CD22

From Wikipedia, the free encyclopedia


CD22 molecule
Identifiers
Symbol(s) CD22; MGC130020; SIGLEC-2; SIGLEC2
External IDs OMIM: 107266 MGI88322 HomoloGene31052
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 933 12483
Ensembl ENSG00000012124 ENSMUSG00000030577
Uniprot P20273 Q3T9T5
Refseq NM_001771 (mRNA)
NP_001762 (protein)
NM_001043317 (mRNA)
NP_001036782 (protein)
Location Chr 19: 40.51 - 40.53 Mb Chr 7: 30.57 - 30.59 Mb
Pubmed search [1] [2]

CD22 or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins.[1] Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.

CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling.

EBV (Ebstein Bar Virus) is known to bind to the B lymphocyte via the CD22 receptor.

An immunotoxin, BL22, that targets this receptor is being tested at the NIH.[2]

[edit] External links

[edit] References

  1. ^ Crocker PR, Clark EA, Filbin M, Gordon S, Jones Y, Kehrl JH, Kelm S, Le Douarin N, Powell L, Roder J, Schnaar RL, Sgroi DC, Stamenkovic K, Schauer R, Schachner M, van den Berg TK, van der Merwe PA, Watt SM, Varki A (1998). "Siglecs: a family of sialic-acid binding lectins". Glycobiology 8 (2): v. doi:10.1093/glycob/8.2.0. PMID 9498912. 
  2. ^ BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia. ClinicalTrials.gov - U.S. National Institutes of Health. Retrieved on 2008-02-19.